Armis Advisers LLC Takes Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Armis Advisers LLC acquired a new stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 44,528 shares of the company’s stock, valued at approximately $432,000.

Several other hedge funds have also modified their holdings of GNOM. Raymond James Financial Inc. acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $2,974,000. Strive Asset Management LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $409,000. Two Sigma Investments LP raised its position in shares of Global X Genomics & Biotechnology ETF by 74.5% in the 4th quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock worth $830,000 after buying an additional 36,500 shares during the period. Citadel Advisors LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $148,000. Finally, Sei Investments Co. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $114,000. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Performance

GNOM opened at $7.70 on Monday. The firm has a 50 day moving average price of $7.87 and a 200 day moving average price of $9.20. The company has a market cap of $40.66 million, a PE ratio of -3.29 and a beta of 1.20. Global X Genomics & Biotechnology ETF has a 1 year low of $6.80 and a 1 year high of $11.88.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.